Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder

Introduction The efficacy and of current antidepressants is insufficient. Esketamine, a new antidepressant administered by nasal route, is available since 2019 in the management of resistant characterized depressive episodes. Objectives To evaluate the response profile of patients to Esketamine in...

Full description

Bibliographic Details
Main Authors: S. Faisant, P. Crublet, R. Bellay, B. Langrée, N. Marie, M. Rojo-Bouton
Format: Article
Language:English
Published: Cambridge University Press 2022-06-01
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933822014171/type/journal_article